EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling

Journal of Clinical Investigation

Volumn 125, Issue 3, 2015, Pages 1228-1242

  Lu, Ankang ^a,b   Zuo, Caojian ^a,b   He, Yuhu ^a,b   Chen, Guilin ^a   Piao, Lingjuan ^a,c   Zhang, Jian ^a   Xiao, Bing ^a   Shen, Yujun ^a   Tang, Juan ^a   Kong, Deping ^a   Alberti, Sara ^a,d   Chen, Di ^a   Zuo, Shenkai ^a   Zhang, Qianqian ^a   Yan, Shuai ^a   Fei, Xiaochun ^b   Yuan, Fei ^b   Zhou, Bin ^a   Duan, Shengzhong ^a   Yu, Yu ^a   Lazarus, Michael ^e   Su, Yunchao ^f   Breyer, Richard M ^g   Funk, Colin D ^h   Yu, Ying ^a   more..

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Ewha Womans University   (South Korea)

^d UNIVERSITY OF CHIETI   (Italy)

^e UNIVERSITY OF TSUKUBA   (Japan)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^h QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; INTERSTITIAL COLLAGENASE; MONOCROTALINE; PROSTAGLANDIN E RECEPTOR 3; RHO FACTOR; TRANSFORMING GROWTH FACTOR BETA1; 5-BROMO-2-METHOXY-N-(3-(NAPHTHALEN-2-YL-METHYLPHENYL)ACRYLOYL)BENZENESULFONAMIDE; PTGER3 PROTEIN, MOUSE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA PROTEIN, MOUSE; SCLEROPROTEIN; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL WALL THICKNESS; ARTICLE; CELL SURFACE; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HYPOXIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR REMODELING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; CELL HYPOXIA; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CELL HYPOXIA; CELLS, CULTURED; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; HYPERTENSION, PULMONARY; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; PULMONARY ARTERY; RATS, SPRAGUE-DAWLEY; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE; RHO GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION; SULFONAMIDES; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR REMODELING;

EID: 84924028882     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI77656     Document Type: Article

References (70)

1. Benza RL, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122(2): 164-172.
2. Shimoda LA, Laurie SS. Vascular remodeling in pulmonary hypertension. J Mol Med (Berl). 2013;91(3):297-309.
3. Lourenco AP, Fontoura D, Henriques-Coelho T, Leite-Moreira AF. Current pathophysiological concepts and management of pulmonary hypertension. Int J Cardiol. 2012;155(3):350-361.
4. Cathcart MC, et al. Cyclooxygenase-2-linked attenuation of hypoxia-induced pulmonary hypertension and intravascular thrombosis. J Pharmacol Exp Ther. 2008;326(1):51-58.
5. Loukanov T, Jaschinski C, Kirilov M, Klimpel H, Karck M, Gorenflo M. Cyclooxygenase-2 expression in lung in patients with congenital heart malformations and pulmonary arterial hypertension. Thorac Cardiovasc Surg. 2013;61(4):307-311.
6. Seta F, Rahmani M, Turner PV, Funk CD. Pulmonary oxidative stress is increased in cyclooxygenase-2 knockdown mice with mild pulmonary hypertension induced by monocrotaline. PLoS One. 2011;6(8):e2343 9.
7. Fredenburgh LE, et al. Absence of cyclooxygenase-2 exacerbates hypoxia-induced pulmonary hypertension and enhances contractility of vascular smooth muscle cells. Circulation. 2008;117(16):2114-2122.
8. McKenzie C, MacDonald A, Shaw AM. Mechanisms of U46619-induced contraction of rat pulmonary arteries in the presence and absence of the endothelium. Br J Pharmacol. 2009;157(4):581-596 .
9. Kozlowska H, et al. EP(3) receptor-mediated contraction of human pulmonary arteries and inhibition of neurogenic tachycardia in pithed rats. Pharmacol Rep. 2012;64(6):1526-1536.
10. Qian YM, Jones RL, Chan KM, Stock AI, Ho JK. Potent contractile actions of prostanoid EP3-receptor agonists on human isolated pulmonary artery. Br J Pharmacol. 1994;113(2):369-374.
11. Jourdan KB, Evans TW, Curzen NP, Mitchell JA. Evidence for a dilator function of 8-iso prostaglandin F2 ? in rat pulmonary artery. Br J Pharmacol. 1997;120(7):1280-1285.
12. Olschewski H, et al. Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther. 2004;102(2):139-153.
13. Yang J, et al. Smad-dependent and smad-independent induction of id 1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo. Circ Res. 2010;107(2):252-262.
14. Christman BW,et al An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension N Engl J Med. 1992 327 2, 70-75.
15. Tuder RM, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999;159(6):1925-1932.
16. Delannoy E, Courtois A, Freund-Michel V, Leblais V, Marthan R, Muller B. Hypoxia-induced hyper reactivity of pulmonary arteries: role of cyclooxygenase-2, isoprostanes, and thromboxane receptors. Cardiovasc Res. 2010;85(3):582-592.
17. Hoshikawa Y, et al. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am J Respir Crit Care Med. 2001;164(2):314-318.
18. Geraci M, et al. Pulmonary prostacyclin synthase overexpression by adenovirus transfection and in transgenic mice. Chest. 1998;114(1):99S.
19. Geraci MW, et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest. 1999;103(11):1509-1515.
20. Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med. 2010;104(1):9-21.
21. Tam FS, Chan K, Borreau JP, Jones RL. The mechanisms of enhancement and inhibition of field stimulation responses of guinea-pig vas deferens by prostacyclin analogues. Br J Pharmacol. 1997;121(7):1413-1421.
22. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese ham ster ovary cells. Br J Pharmacol. 1997;122(2):217-224.
23. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999;79(4):1193-1226.
24. Orie NN, Clapp LH. Role of prostanoid IP and EP receptors in mediating vasorelaxant responses to PGI2 analogues in rat tail artery: Evidence for Gi/o modulation via EP3 receptors. Eur J Pharma col. 2011;654(3):258-265.
25. Abramovitz M, et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophy s Acta. 2000;1483(2):285-293.
26. Whittle BJ, Silverstein AM, Mottola DM, Clapp LH. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. Biochem Pharmacol. 2012;84(1):68-75.
27. Kuwano K, Hashino A, Noda K, Kosugi K, Kuwabara K. A long-Acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl) amino]butoxy}-N-(methylsulfonyl)acetam ide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl) (isopropyl)amino]butoxy} acetic acid (MRE-269), on rat pulmonary artery. J Pharmacol Exp Ther. 2008;326(3):691-699.
28. Morrison K, Studer R, Ernst R, Haag F, Kauser K, Clozel M. Differen tial effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery. J Pharmacol Exp Ther. 2012;343(3):547-555.
29. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol. 2001;41:661-690.
30. Kotelevets L, Foudi N, Louedec L, Couvelard A, Chastre E, Norel X. A new mRNA splice variant coding fo r the human EP3-I receptor isoform. Prostaglandins Leukot Essent Fatty Acids. 2007;77(3):195-201.
31. Zhang J, et al. Cyclooxygenase-2-derived prostaglandin E2 promotes injury-induced vascular neoin timal hyperplasia through the E-prostanoid 3 receptor. Circ Res. 2013;113(2):104-114.
32. Jones RL, Woodward DF, Wang JW, Clark RL. Roles of affinity and lipophilicity in the slow kinetics of pr ostanoid receptor antagonists on isolated smooth muscle preparations. Br J Pharmacol. 2011;162(4):863-879.
33. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 2012;122(12):4306-4313.
34. Humbert M, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12):13S-24S.
35. Wu X, Chang MS, Mitsialis SA, Kourembanas S. Hypoxia regulates bone morphogenetic protein signaling through C-terminal-binding protein 1. Circ Res. 2006;99(3):240-247.
36. Ma W, et al. Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. J Clin Invest. 2011;121(11):4548-4566.
37. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol. 1993;9:541-573.
38. Wipff PJ, Hinz B. Integrins and the activation of latent transforming growth factor beta1-An intimate relationship. Eur J Cell Biol. 2008;87(8):601-615.
39. Leask A, Abraha m DJ. TGF-? signaling and the fibrotic response. FASEB J. 2004;18(7):816-827.
40. Lee SH, Dominguez R. Regulation of actin cytoskeleton dynamics in cells. Mol Cells. 2010;29(4):311-325.
41. Mori H, et al. CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J. 2002;21(15):3949-3959.
42. Clark ES, Whigham AS, Yarbrough WG, Weaver AM. Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res. 2007;67(9):4227-4235.
43. Schram K, Ganguly R, No EK, Fang X, Thong FS, Sweeney G. Regulation of MT1-MMP and MMP-2 by leptin in cardiac fibroblasts involves Rho/ROCK-dependent actin cytoskeletal reorganization and leads to e nhanced cell migration. Endocrinology. 2011;152(5):2037-2047.
44. Hatae N, Sugimoto Y, Ichikawa A. Prostaglandin receptors: advances in the study of EP3 receptor signaling. J Biochem. 2002;131(6):781-784.
45. Macias-Perez IM, Zent R, Carmosino M, Breyer MD, Breyer RM, Pozzi A. Mouse EP3 ?, ?, and ? receptor variants reduce tumor cell proliferation and tumorigenesis in vivo. J Biol Chem. 2008;283(18):12538-12545.
46. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31(5):986-1000.
47. Yan G, et al. Regulation of rat intrapulmonary arterial tone by arachidonic acid and prostaglandin E2 during hypoxia. PLoS One. 2013;8(8):e73839.
48. Ichinose F, et al. Cytosolic phospholipase A(2) in hypoxic pulmonary vasoconstriction. J Clin Invest. 2002;109(11):1493-1500.
49. Lai YJ, et al. Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension. Am J Respir Crit Care Med. 2008;178(2):188-196.
50. Cracowski JL, et al. Increased lipid peroxidation in patients with pulmonary hypertension. Am J Respir Crit Care Med. 2001;164(6):1038-1042.
51. Cracowski JL, et al. Independent association of urinary F2-isoprostanes with survival in pulmonary arterial hypertension. Chest. 2012;142(4):869-876.
52. Botney MD, Bahadori L, Gold LI. Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factor-?. Am J Pathol. 1994;144(2):286-295.
53. Arcot SS, Lipke DW, Gillespie MN, Olson JW. Alterations of growth factor transcripts in rat lungs during development of monocrotaline-induced pulmonary hypertension. Biochem Pharm acol. 1993;46(6):1086-1091.
54. Perkett EA, Lyons RM, Moses HL, Brigham KL, Meyrick B. Transforming growth factor-? activity in sheep lung lymph during the development of pulmonary hypertensi on. J Clin Invest. 1990;86(5):1459-1464.
55. Long L, et al. Altered bone morphogenetic protein and transforming growth factor-? signaling in rat models of pulmonary hypertension: potential for activ in receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation. 2009;119(4):566-576.
56. Irie A, Sugimoto Y, Namba T, Asano T, Ichikawa A, Negishi M. The C-terminus of the prostaglandin-E-receptor EP3 subtype is essential for activation of GTP-binding protein. Eur J Biochem. 1994;224(1):161-166.
57. Hasegawa H,Katoh H,Yamaguchi Y,Nakamura K,Futakawa S,Negishi M Different membrane targeting of prostaglandin EP3 receptor isoforms dependent on their carboxy-terminal tail structures FEBS Lett. 2000 473 1, 76-80.
58. Rifkin DB. La tent transforming growth factor-? (TGF-?) binding proteins: orchestrators of TGF-? availability. J Biol Chem. 2005;280(9):7409-7412.
59. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol. 2000;1(3):169-178.
60. Kozasa T, Hajicek N, Chow CR, Suzuki N. Signalling mechanisms of RhoGTPase regulation by the heterotrimeric G proteins G12 and G13. J Biochem. 2011;150(4):357-369.
61. Wang M, et al. Matrix metalloproteinase 2 activation of transforming growth factor-?1 (TGF-?1) and TGF-?1-type II receptor signaling within the aged arterial wall. Arterioscler Thromb Vasc Biol . 2006;26(7):1503-1509.
62. Kobayashi K, Murata T, Hori M, Ozaki H. Prostaglandin E2-prostanoid EP3 signal induces vascular contraction via nPKC and ROCK activation in rat mesenteric artery. Eur J Pharmacol. 2011;660(2):375-380.
63. Thumkeo D, Watanabe S, Narumiya S. Physiological roles of Rho and Rho effectors in mammals. Eur J Cell Biol. 2013;92(10):303-315.
64. Schram K, Wong MM, Palanivel R, No EK, Dixon IM, Sweeney G. Increased expression and cell surface localization of MT1-MMP plays a role in stimulation of MMP-2 activity by leptin in neonatal rat cardiac myofi broblasts. J Mol Cell Cardiol. 2008;44(5):874-881.
65. Abe K, et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res. 2004;94(3):385-393.
66. Oka M, et al. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res. 2007;100(6):923-929.
67. Abe K, et al. Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice. J Cardiovasc Pharmacol. 2006;48(6):280-285.
68. Fukumoto Y, et al. Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension. Circ J. 2013;77(10):2619-2625.
69. Lazarus M, et al. EP3 prostaglandin receptors in the median preoptic nucleus are critical for fever responses. Nat Neurosci. 2007;10(9):1131-1133.
70. Wang Z, Lakes RS, Golob M, Eickhoff JC, Chesler NC. Changes in large pulmonary arterial viscoelasticity in chronic pulmonary hypertension. PLoS One. 2013;8(11):e78569.